ストックスクリーナーアプリを入手
0.455
1.54%
0.0069
アフターアワーズ：
.45
-0.005
-1.10%
前日終値:
$0.4481
開ける：
$0.461
24時間の取引高:
512.36K
Relative Volume:
2.11
時価総額：
$21.31M
収益：
$10.85M
当期純損益:
$-51.31M
株価収益率:
-0.6174
EPS:
-0.737
ネットキャッシュフロー:
$-36.77M
1週間 パフォーマンス:
-5.29%
1か月 パフォーマンス:
-40.04%
6か月 パフォーマンス:
-65.53%
1年 パフォーマンス:
-79.69%
1日の値動き範囲:
$0.4393
$0.4899
1週間の範囲:
$0.4254
$0.526
52週間の値動き範囲:
$0.4254
$2.41
Inspiremd Inc Stock (NSPR) Company Profile
Compare NSPR vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NSPR
Inspiremd Inc
|
0.455 | 21.31M | 10.85M | -51.31M | -36.77M | -0.737 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Inspiremd Inc Stock (NSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | 開始されました | Maxim Group | Buy |
| 2016-01-07 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 開始されました | Oppenheimer | Outperform |
Inspiremd Inc (NSPR) 最新ニュース
InspireMD (NSPR) Climbs 8.5% to $0.52 as Shares Reclaim the $0.50 LevelButterfly Setup - https://www.siam.in/
InspireMD (NSPR) Climbs 8.5% to $0.52 as Shares Reclaim the $0.50 LevelMomentum Trade - https://www.dars.gov.et/
InspireMD (NASDAQ:NSPR) Will Have To Spend Its Cash Wisely - Simply Wall Street
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com UK
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com Nigeria
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com Nigeria
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com UK
Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan
InspireMD (NSPR) director Gary S. Roubin acquired and disposed of warrants with different exercise prices. - Stock Titan
InspireMD amends certain Series J, Series K warrants - Medical Buyer
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD (NASDAQ: NSPR) Revises Series J and K Warrants with $0.7674 Exercise Price and FDA-Linked Expiry by May 2028 - kalkinemedia.com
InspireMD Amends Warrants for Up to $11 Million Tied to FDA Approval - Minichart
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com South Africa
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - manilatimes.net
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - GlobeNewswire Inc.
An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan
InspireMD amends warrants tied to FDA approval timeline - Investing.com
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com Canada
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com UK
InspireMD approves 221,666 share inducement grant for new hire - scanx.trade
Full Transcript: InspireMD Q2 2026 Earnings Call - Benzinga
InspireMD announces inducement grants - Medical Buyer
Inspiremd Stock Price Forecast. Should You Buy NSPR? - StockInvest.us
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
InspireMD Inc. (NSPR) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - valueresearchonline.com
InspireMD Inc. Series B Warrants (NSPRZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc. Series B Warrants (NSPRZ) Peer Comparison – Compare with Others - Value Research
InspireMD Earnings Call: Recall Pain, Regulatory Potential - TipRanks
InspireMD Inc. Series B Warrants (NSPRZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD Inc. (NSPR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusETF Creation Redemption - siam.in
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusStandard Deviation - dars.gov.et
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $3 - Moomoo
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate - Sci-Tech Today
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $3 - Moomoo
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD total revenue down 0.4% to USD 1,771,000 in Q2 2026 - Medical Buyer
Form 8K InspireMD Inc For: 17 August By Investing.com - Investing.com South Africa
InspireMD Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
InspireMD Q2 revenue holds at $1.8 million - grafa.com
InspireMD, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
InspireMD Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com Nigeria
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com
Inspiremd Inc (NSPR) 財務データ
収益
当期純利益
現金流量
EPS
Inspiremd Inc (NSPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gleason Shane Thomas | Chief Commercial Officer |
May 19 '26 |
Sale |
1.01 |
22,778 |
23,006 |
1,053,882 |
| Stuka Paul | Director |
May 14 '26 |
Buy |
1.15 |
5,000 |
5,750 |
647,871 |
| Stuka Paul | Director |
May 13 '26 |
Buy |
1.16 |
10,000 |
11,575 |
642,871 |
| Slosman Marvin | CEO and President |
May 12 '26 |
Buy |
1.20 |
21,000 |
25,200 |
3,556,658 |
| Stuka Paul | Director |
May 11 '26 |
Buy |
1.19 |
10,000 |
11,900 |
632,871 |
| Stuka Paul | Director |
May 08 '26 |
Buy |
1.16 |
65,626 |
76,126 |
622,871 |
| ROUBIN GARY S | Director |
May 07 '26 |
Buy |
1.18 |
90,000 |
106,200 |
834,478 |
| Ward Scott R. | Director |
May 07 '26 |
Buy |
1.15 |
73,255 |
84,243 |
237,096 |
| Stuka Paul | Director |
May 07 '26 |
Buy |
1.15 |
6,378 |
7,335 |
531,599 |
| Ward Scott R. | Director |
May 06 '26 |
Buy |
1.15 |
15,995 |
18,394 |
163,841 |
8.76%
12.34%
大文字化:
|
ボリューム (24 時間):